PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34662393-1	2022	Covalent Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have proven to be highly beneficial in the treatment of chronic lymphocytic leukemia (CLL).	ibrutinib	57-66	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	9-31	
34662393-1	2022	Covalent Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have proven to be highly beneficial in the treatment of chronic lymphocytic leukemia (CLL).	ibrutinib	57-66	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	33-36	
34662393-11	2022	Thus, non-covalent BTK/ITK inhibitors such as vecabrutinib may be efficacious in C481S BTK mutant CLL, while preserving the T-cell immunomodulatory function of ibrutinib.	ibrutinib	160-169	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	19-22